Adama Biologics reiterates revenue of at least $530 million for 2026 and raises minimum adjusted EBITDA to at least $275 million as demand for ASCENIV accelerates ( NASDAQ:ADMA ) .
Adama Biologics reiterates revenue of at least $530 million for 2026 and raises minimum adjusted EBITDA to at least $275 million as demand for ASCENIV accelerates ( NASDAQ:ADMA ) .
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in